Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

REGN5093-M114

Copy Product Info
🥰Excellent

Synonyms:

Catalog No. T9901A-768 Copy Product Info
🥰Excellent
REGN5093-M114 is a bispecific antibody-drug conjugate (ADC) that targets two epitopes of the MET receptor tyrosine kinase, effectively inhibiting NSCLC cell proliferation and demonstrating antitumor activity in mouse models. REGN5093-M114 is composed of the human monoclonal anti-MET antibody Davutamig and a tubulin-inhibiting linker-payload.

REGN5093-M114

Pack SizePriceUSA StockGlobal StockQuantity
1 mgInquiryInquiryInquiry
5 mgInquiryInquiryInquiry
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
REGN5093-M114 is a bispecific antibody-drug conjugate (ADC) that targets two epitopes of the MET receptor tyrosine kinase, effectively inhibiting NSCLC cell proliferation and demonstrating antitumor activity in mouse models. REGN5093-M114 is composed of the human monoclonal anti-MET antibody Davutamig and a tubulin-inhibiting linker-payload.
Application
FACS
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Storage & Solubility Information
StorageStore at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: